» Articles » PMID: 12163387

Establishment and Validation of Real-time Polymerase Chain Reaction Method for CDH1 Promoter Methylation

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2002 Aug 7
PMID 12163387
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrant methylation of the promoter region has emerged as the major mechanism for silencing tumor suppressor genes. However, for some genes, such as E-cadherin (CDH1), methylation and protein expression demonstrate considerable heterogeneity, making correlations difficult. We compared methylation and protein expression status of CDH1 in 56 primary breast carcinomas using semiquantitative assays. Aberrant CDH1 methylation was studied by methylation-specific polymerase chain reaction (MSP) and semiquantitative real-time MSP assays. The Cdh1 expression was investigated by immunostaining on archival formalin-fixed sections from 34 primary carcinomas and their accompanying normal epithelium and preinvasive and metastatic lesions. Membrane-specific Cdh1 expression in the neoplastic cells was quantified by image analysis using an automated cellular imaging system and a continuous score. Aberrant promoter methylation of the CDH1 was present in 24 of 56 (43%) breast carcinomas by MSP assay. There was excellent concordance between the standard MSP assay and the real-time assay (91%, P < 0.0001). The concordance between loss of Cdh1 expression and CDH1 methylation by standard MSP was 71% (P = 0.02). Furthermore, there was a strong correlation between the semiquantitative assays for methylation and protein expression (r = 0.47, P = 0.005). We conclude that promoter methylation of CDH1 significantly correlated with the Cdh1 expression level, demonstrating that epigenetic silencing is a valid pathway for silencing of tumor suppressor genes in primary breast carcinomas.

Citing Articles

A comprehensive diagnostic scheme of morphological combined molecular methylation under bronchoscopy.

Zhang J, Huang H, Yu F, Bian Y, Wang R, Liu H Front Oncol. 2023; 13:1133675.

PMID: 37182143 PMC: 10174301. DOI: 10.3389/fonc.2023.1133675.


() Gene Methylation in Human Breast Cancer: Critical Appraisal of a Long and Twisted Story.

Bucker L, Lehmann U Cancers (Basel). 2022; 14(18).

PMID: 36139537 PMC: 9497067. DOI: 10.3390/cancers14184377.


A panel of DNA methylated markers predicts metastasis of pNM gastric carcinoma: a prospective cohort study.

Liu Z, Cheng X, Zhang L, Zhou J, Deng D, Ji J Br J Cancer. 2019; 121(7):529-536.

PMID: 31431673 PMC: 6889426. DOI: 10.1038/s41416-019-0552-0.


Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review.

Jia M, Gao X, Zhang Y, Hoffmeister M, Brenner H Clin Epigenetics. 2016; 8:25.

PMID: 26941852 PMC: 4776403. DOI: 10.1186/s13148-016-0191-8.


Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.

Huang R, Ding P, Yang F Drug Des Devel Ther. 2015; 9:5277-85.

PMID: 26425077 PMC: 4583122. DOI: 10.2147/DDDT.S86929.


References
1.
Mareel M, Bracke M, VAN Roy F . Cancer metastasis: negative regulation by an invasion-suppressor complex. Cancer Detect Prev. 1995; 19(5):451-64. View

2.
Pierceall W, Woodard A, Morrow J, Rimm D, Fearon E . Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines. Oncogene. 1995; 11(7):1319-26. View

3.
Takeichi M . Morphogenetic roles of classic cadherins. Curr Opin Cell Biol. 1995; 7(5):619-27. DOI: 10.1016/0955-0674(95)80102-2. View

4.
Herman J, Graff J, Myohanen S, Nelkin B, Baylin S . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821-6. PMC: 38513. DOI: 10.1073/pnas.93.18.9821. View

5.
Berx G, Cleton-Jansen A, Strumane K, de Leeuw W, Nollet F, VAN Roy F . E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996; 13(9):1919-25. View